Oral Oxytocin's Effects on Attention Control

NCT04493515 | Unknown

• 1 other identifier: UESTC-neuSCAN-69
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The main aim of the study is to investigate whether orally administered oxytocin (24IU) could modulate attention control using a social-emotional saccade/antisaccade eye-tracking paradigm.

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• Effect of oral oxytocin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli

  Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the oxytocin and placebo treatment conditions

  45 minutes - 100 minutes after treatment

• Effect of oral oxytocin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli

  Comparison between social-specific error rates of saccade/antisaccade between the oxytocin and placebo treatment conditions.

  45 minutes - 100 minutes after treatment

Secondary Outcomes (2)

• Emotion-specific effects of oral oxytocin administration on saccade/antisaccade latencies towards the separate facial emotions

  45 minutes - 100 minutes after treatment

• Emotion-specific effects of oral oxytocin administration on saccade/antisaccade error rates for the separate facial emotions

  45 minutes - 100 minutes after treatment

Study Arms (2)

Oral Oxytocin

EXPERIMENTAL

Oxytocin orally (24 IU)

Drug: Oral Oxytocin

Oral Placebo

PLACEBO COMPARATOR

Placebo orally (24 IU, identical ingredients, except the active agent)

Drug: Oral Placebo

Interventions

Oral Oxytocin DRUG

Administration of oxytocin orally (24 IU)

Oral Oxytocin

Oral Placebo DRUG

Administration of placebo orally (24 IU)

Oral Placebo

Eligibility Criteria

• Age: 18 Years - 30 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male, healthy participants
• Non smokers

You may not qualify if:

• Previous or current medical, psychiatric, neurological disorder
• Regular medication
• Use of any psychoactive substances in the 24 hours before experiment
• Contra-indications for oxytocin
• Contra-indications for eye-tracking data acquisition

Sponsors & Collaborators

• University of Electronic Science and Technology of China: lead

Study Sites (1)

University of Electronic Science and Technology of China(UESTC)

Chengdu, Sichuan, 611731, China

RECRUITING

MeSH Terms

Interventions

Oxytocin

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Posterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Study Officials

• Keith Kendrick, PhD

  University of Electronic Science and Technology of China (UESTC)

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Zhuang Qian, MD

CONTACT

13086663679; zq19910362@126.com

Xu Xiaolei, PhD

CONTACT

18780140034; rabby_uestc@outlook.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design

Study Record Dates

• First Submitted: July 27, 2020
• First Posted: July 30, 2020
• Study Start: July 28, 2020
• Primary Completion: December 31, 2020
• Study Completion: December 31, 2021
• Last Updated: July 30, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)